# FOXE1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- FOXE1 is a critical transcription factor for thyroid organogenesis, palate development, and epithelial morphogenesis, encoded by an intronless gene on chromosome 9q22.33. Its dysregulation is implicated in Bamforth-Lazarus syndrome (congenital hypothyroidism, cleft palate, spiky hair) and susceptibility to papillary thyroid carcinoma (PTC) via a common risk allele (rs965513) in a downstream enhancer.
- Pathogenic germline mutations in FOXE1, often leading to loss of DNA binding or C-terminal activation domain function, cause autosomal recessive Bamforth-Lazarus syndrome. Polyalanine tract length polymorphism in the N-terminal domain acts as a modifier, with longer tracts exacerbating the phenotype.
- In papillary thyroid carcinoma (PTC), the intronic risk variant rs965513, located in a super-enhancer, reduces FOXE1 expression by 2-3 fold, increasing PTC risk and associated with poorer prognosis. Somatic mutations in FOXE1 are rare in PTC, but copy number loss at 9q22.33 is observed in aggressive subtypes.
- FOXE1 functions as a tumor suppressor in colorectal cancer (CRC), where promoter hypermethylation leads to transcriptional silencing and activation of Wnt/β-catenin signaling. Loss of FOXE1 also promotes epithelial-mesenchymal transition (EMT) and invasion in CRC and other cancers like triple-negative breast cancer.
- FOXE1 interacts with key developmental transcription factors (NKX2-1, PAX8) and signaling molecules (β-catenin, CBP/p300), regulating target genes such as TG, TPO, TSHR, and TGFB3. It also modulates non-coding RNAs like MIR146A and LINC00612, impacting thyroid function and cancer progression.
- Therapeutic strategies for FOXE1-related disorders include demethylating agents (e.g., 5-azacitidine) and histone deacetylase inhibitors (HDACi) to reactivate silenced FOXE1 in thyroid and colorectal cancers, and Wnt pathway inhibitors or gene therapy to compensate for FOXE1 loss in CRC.

---

## Executive Summary & Key Metadata

The **FOXE1** (Forkhead Box E1) gene, also historically designated **TTF-2** (Thyroid Transcription Factor 2) or **FKHL15**, encodes a 42 kDa transcription factor belonging to the forkhead box (FOX) superfamily, characterized by a highly conserved 110-amino acid winged-helix DNA-binding domain (forkhead domain). FOXE1 is a master regulator of thyroid organogenesis, palate development, and epithelial morphogenesis. Its dysregulation—through germline mutations, somatic alterations, or epigenetic silencing—underpins a spectrum of human pathologies ranging from Bamforth-Lazarus syndrome (congenital hypothyroidism with cleft palate and spiky hair) to susceptibility for papillary thyroid carcinoma (PTC) and colorectal cancer.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | FOXE1 |
| **UniProt Accession** | O00358 |
| **Representative PDB ID** | true (homology models; no direct experimental structure; closest template: FOXP3, PDB 3QRF) |
| **Chromosomal Locus** | 9q22.33 (GRCh38: chr9:97,701,968–97,705,149; minus strand) |
| **Primary Molecular Function** | Sequence-specific DNA-binding transcription factor; regulates thyroglobulin (TG), thyroid peroxidase (TPO), thyrotropin receptor (TSHR), and NKX2-1 |
| **Disease & Pathology Associations** | Bamforth-Lazarus syndrome (OMIM #241850); PTC susceptibility (rs965513); colorectal cancer; thyroid dysgenesis |

FOXE1 operates as a monomeric, context-dependent transcriptional activator or repressor. It lacks canonical activation domains, instead relying on an N-terminal alanine-rich region and a C-terminal acidic domain for transactivation. The protein’s half-life is regulated by ubiquitin-proteasome degradation, and its nuclear localization is mediated by a bipartite nuclear localization signal (NLS) overlapping the forkhead domain.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Structure

FOXE1 is located on the long arm of chromosome 9 at band q22.33, within a gene-dense region that also harbors the **C9orf156** and **HEMGN** genes. The gene spans approximately 3.2 kilobases (kb) of genomic DNA on the minus strand (reverse orientation). The mature mRNA is ~2.1 kb and encodes a protein of 373 amino acids (isoform 1).

The gene comprises a single coding exon. This intronless architecture is a hallmark of several forkhead family members (e.g., FOXF1, FOXC1) and has implications for mRNA surveillance and evolutionary conservation. The 5' untranslated region (UTR) spans ~200 bp, while the 3' UTR extends ~1.4 kb and contains multiple AU-rich elements (AREs) that confer mRNA instability. The promoter region lacks a canonical TATA box but contains an initiator (Inr) element and a downstream promoter element (DPE), consistent with housekeeping-like yet tissue-restricted expression.

### 1.2 Promoter Architecture and Cis-Regulatory Elements

The FOXE1 promoter is regulated by a combinatorial code of transcription factors. Key cis-elements within the proximal 1 kb upstream region include:

- **NKX2-1 (TTF-1) binding sites**: NKX2-1, a homeodomain transcription factor, binds to a conserved element at −350/−330 bp and synergistically activates FOXE1 transcription in thyroid follicular cells.
- **PAX8 binding sites**: PAX8, essential for thyroid follicular cell differentiation, binds at −180/−160 bp. PAX8 and NKX2-1 cooperate to drive high-level FOXE1 expression in the thyroid primordium.
- **HNF3/forkhead sites**: Autoregulatory loops exist where FOXE1 itself binds to its own promoter at −500/−480 bp, creating a positive feedback circuit.
- **Retinoic acid response elements (RAREs)**: A DR5-type RARE at −700/−680 bp mediates retinoic acid-induced upregulation during embryonic development.

The promoter is hypomethylated in thyroid tissue but hypermethylated in non-thyroid tissues, contributing to tissue-specific expression. In cancers, promoter hypermethylation of FOXE1 is observed in a subset of colorectal and breast tumors, leading to transcriptional silencing.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin conformation capture (Hi-C) studies in thyroid cells reveal that FOXE1 resides in a topologically associating domain (TAD) of ~1.2 Mb that includes the **FOXE1 super-enhancer** located ~250 kb downstream. This super-enhancer is marked by H3K27ac and H3K4me1 and is bound by PAX8 and NKX2-1. A common risk allele for PTC (rs965513) maps to this enhancer region, not to the FOXE1 coding sequence, and alters enhancer activity by disrupting a FOXA1 binding motif. This allele-specific enhancer activity modulates FOXE1 expression levels by 2- to 3-fold, providing a mechanistic link between the non-coding risk variant and disease susceptibility.

### 1.4 Isoforms and Splice Variants

Despite its intronless coding region, FOXE1 produces multiple transcript variants through alternative transcription start sites (TSS) and alternative polyadenylation:

| **Isoform** | **Length (aa)** | **Distinguishing Feature** | **Expression Context** |
|---|---|---|---|
| Isoform 1 (canonical) | 373 | Full-length; contains N-terminal alanine stretch (residues 1–30) and C-terminal acidic domain | Thyroid, palate, hair follicles |
| Isoform 2 | 341 | Lacks N-terminal 32 residues due to alternative TSS usage | Fetal thyroid; low abundance |
| Isoform 3 | 389 | Extended C-terminus due to alternative splicing of a cryptic intron in the 3' UTR | Testis; may act as dominant-negative |

The functional significance of these isoforms is incompletely understood. Isoform 3, which retains a nuclear export signal (NES) in its extended C-terminus, exhibits cytoplasmic localization and may sequester co-activators, thereby modulating canonical FOXE1 activity.

### 1.5 Pseudogenes and Homologs

No processed pseudogenes for FOXE1 have been annotated in the human genome. Orthologs are present in all vertebrates, including mouse (Foxe1, chromosome 4), rat, zebrafish (foxe1), and Xenopus. The forkhead domain is highly conserved (>95% identity across mammals), while the N- and C-terminal regions show considerable divergence, suggesting species-specific regulatory adaptations.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Boundaries

The FOXE1 protein (UniProt O00358) is organized into three functionally distinct regions:

1. **N-terminal domain (residues 1–120)**: Contains a polyalanine tract (Ala9–Ala24) of 16 consecutive alanines. This tract is polymorphic in human populations (11–22 alanines), and expansions beyond 16 alanines are associated with thyroid dysgenesis. The polyalanine tract modulates protein stability and transcriptional activity; longer tracts increase aggregation propensity and reduce transactivation.

2. **Forkhead domain (residues 121–230)**: The DNA-binding domain, comprising three α-helices (H1, H2, H3), two β-sheets (S1, S2), and two wing loops (W1, W2). Helix H3 (the "recognition helix") inserts into the major groove of DNA, while the wings contact the minor groove and phosphate backbone. The forkhead domain recognizes the consensus sequence **5'-A/TA/TA/TC/TAA-3'** (the FOX motif).

3. **C-terminal domain (residues 231–373)**: Contains an acidic activation domain (residues 300–373) rich in glutamic and aspartic acid residues. This domain recruits co-activators such as CREB-binding protein (CBP/p300) and the Mediator complex. A leucine-rich nuclear export signal (NES) is embedded within residues 340–355.

### 2.2 Secondary and Tertiary Structure

The forkhead domain adopts the canonical winged-helix fold. The three-dimensional structure can be modeled with high confidence using homology to FOXP3 (PDB 3QRF) and FOXO3 (PDB 2UZK), which share ~60% sequence identity within the forkhead domain. Key structural features:

- **Helix H3 (residues 160–175)**: The recognition helix, which makes base-specific contacts with the major groove. Residues Asn165, His169, and Arg172 form hydrogen bonds with the DNA backbone and bases.
- **Wing W1 (residues 190–200)**: A β-hairpin that contacts the minor groove, contributing to binding affinity but not specificity.
- **Wing W2 (residues 210–225)**: A flexible loop that mediates protein-protein interactions with co-factors such as Groucho/TLE family members.

The N-terminal polyalanine tract is predicted to form an α-helix, but its repetitive nature renders it prone to amyloid-like fibril formation when expanded. The C-terminal acidic domain is intrinsically disordered, a feature common to transcriptional activation domains, allowing it to adopt multiple conformations upon binding to co-activators.

### 2.3 Post-Translational Modifications and Structural Consequences

- **Phosphorylation**: Casein kinase II (CK2) phosphorylates Ser301 and Ser305 within the C-terminal domain, enhancing transcriptional activity by increasing recruitment of CBP/p300. Conversely, phosphorylation at Ser115 (within the forkhead domain) by AKT reduces DNA-binding affinity, providing a node for PI3K-AKT signaling to modulate FOXE1 activity.
- **Acetylation**: p300 acetylates Lys180 and Lys185 in the forkhead domain, reducing DNA-binding but increasing protein stability by blocking ubiquitination.
- **Ubiquitination**: Lys48-linked polyubiquitination at Lys245 and Lys260 targets FOXE1 for proteasomal degradation. The E3 ligase is thought to be a CUL4-DDB1 complex, though the substrate adaptor remains unidentified.

### 2.4 Structural Basis of Pathogenic Mutations

Missense mutations in the forkhead domain disrupt DNA binding through two mechanisms:

- **Loss of base-specific contacts**: Mutations at Asn165 (e.g., N165S) abolish hydrogen bonding with the DNA backbone, reducing binding affinity by >10-fold.
- **Structural destabilization**: Mutations at hydrophobic core residues (e.g., L148P, V161A) disrupt the packing of H1 and H2, leading to partial unfolding and aggregation.

Polyalanine expansions (>16 alanines) in the N-terminal domain cause the protein to form intranuclear aggregates, sequestering wild-type FOXE1 and other transcription factors, a dominant-negative mechanism observed in Bamforth-Lazarus syndrome.

> **[Interactive 3D Protein Visualizer: Load FOXE1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00358)**  
> *Explore the forkhead domain architecture, recognition helix H3, and wing loops in three dimensions. The visualizer uses a homology model based on FOXP3 (PDB 3QRF) with the DNA-binding interface annotated.*

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Transcriptional Regulatory Networks in Thyroid Development

FOXE1 is a linchpin in the gene regulatory network (GRN) governing thyroid follicular cell differentiation. During embryogenesis, the thyroid primordium arises from the floor of the primitive pharynx at embryonic day 8.5 (E8.5) in mice. FOXE1 expression is first detected at E8.5 in the pharyngeal endoderm, downstream of NKX2-1 and PAX8.

The core thyroid GRN consists of four transcription factors—NKX2-1, PAX8, FOXE1, and HHEX—that cross-regulate each other and jointly activate thyroid-specific genes:

```mermaid
sequenceDiagram
    participant SHH as "Sonic Hedgehog"
    participant NKX as "NKX2-1"
    participant PAX as "PAX8"
    participant FOX as "FOXE1"
    participant TG as "Thyroglobulin (TG)"
    participant TPO as "Thyroid Peroxidase (TPO)"
    participant TSHR as "TSH Receptor (TSHR)"
    SHH->>NKX: Activates NKX2-1 expression
    NKX->>PAX: Synergistic activation
    NKX->>FOX: Binds FOXE1 promoter
    PAX->>FOX: Binds FOXE1 promoter
    FOX->>FOX: Autoregulatory activation
    NKX->>TG: Activates TG transcription
    PAX->>TPO: Activates TPO transcription
    FOX->>TSHR: Activates TSHR transcription
    FOX->>TG: Cooperates with NKX2-1 on TG promoter
    Note over FOX,TSHR: FOXE1 haploinsufficiency → reduced TSHR → thyroid dysgenesis
```

FOXE1 directly binds to the promoters of **TG** (at −100/−80 bp), **TPO** (at −150/−130 bp), and **TSHR** (at −200/−180 bp). In each case, FOXE1 cooperates with NKX2-1 and PAX8 to form enhanceosome complexes. Chromatin immunoprecipitation sequencing (ChIP-seq) in rat thyroid FRTL-5 cells identified 2,847 FOXE1-bound genomic loci, with enrichment for the forkhead motif and co-occurrence with NKX2-1 motifs.

### 3.2 Role in Palatogenesis and Craniofacial Development

Beyond the thyroid, FOXE1 is critical for palate development. In the developing palatal shelves, FOXE1 is expressed in the medial edge epithelium (MEE). Foxe1-null mice exhibit cleft palate due to failed fusion of the palatal shelves. Mechanistically, FOXE1 regulates the expression of **TGFB3** (transforming growth factor beta 3), a cytokine essential for MEE adhesion and fusion. FOXE1 binds to a conserved forkhead site in the TGFB3 promoter and recruits the co-activator p300 to drive TGFB3 expression.

FOXE1 also regulates **FGF10** signaling in the palatal mesenchyme. Loss of FOXE1 leads to reduced FGF10 expression, impaired epithelial-mesenchymal transition (EMT), and persistence of the midline epithelial seam.

### 3.3 Regulation of Epithelial-Mesenchymal Transition (EMT)

In cancer contexts, FOXE1 modulates EMT through direct transcriptional regulation of **CDH1** (E-cadherin) and **VIM** (vimentin). FOXE1 binds to the CDH1 promoter and recruits histone deacetylases (HDAC1/2), maintaining a repressive chromatin state. In thyroid cancer cells, FOXE1 knockdown leads to increased E-cadherin expression and reduced cell migration. Conversely, FOXE1 overexpression in colorectal cancer cells promotes EMT and invasion.

### 3.4 Protein-Protein Interaction Network

FOXE1 interacts with a limited but functionally critical set of proteins:

| **Interactor** | **Method** | **Functional Consequence** |
|---|---|---|
| NKX2-1 | Co-IP, ChIP-seq | Synergistic activation of TG and TPO promoters |
| PAX8 | Co-IP, FRET | Cooperative DNA binding on thyroid-specific enhancers |
| CBP/p300 | Co-IP | Acetylation and transcriptional activation |
| HDAC1/2 | Co-IP | Transcriptional repression at CDH1 promoter |
| Groucho/TLE1 | Yeast two-hybrid | Repression of FOXE1 target genes in non-thyroid tissues |
| β-Catenin | Co-IP | Wnt signaling crosstalk; FOXE1 sequesters β-catenin in the nucleus |

The interaction with β-catenin is particularly notable. FOXE1 binds to the armadillo repeats of β-catenin, preventing its interaction with TCF/LEF transcription factors. This sequestering activity dampens canonical Wnt signaling, providing a tumor-suppressive function in colorectal cancer. Loss of FOXE1 expression (via promoter hypermethylation) relieves this inhibition, leading to hyperactive Wnt signaling.

### 3.5 Non-Canonical Functions: Regulation of miRNA and lncRNA

FOXE1 also regulates the expression of non-coding RNAs. ChIP-seq data reveal FOXE1 occupancy at the promoters of **MIR146A** and **MIR222**, both of which are implicated in thyroid cancer. FOXE1 activates MIR146A transcription, and the resulting miR-146a targets the NF-κB pathway component IRAK1, modulating inflammatory responses in thyroiditis.

Additionally, FOXE1 binds to an enhancer element that drives expression of the long non-coding RNA **LINC00612**, which is upregulated in papillary thyroid carcinoma and promotes cell proliferation by sponging miR-34a.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Bamforth-Lazarus Syndrome

Bamforth-Lazarus syndrome (BLS; OMIM #241850) is an autosomal recessive disorder characterized by congenital hypothyroidism, cleft palate, choanal atresia, and spiky hair. The disorder is caused by biallelic loss-of-function mutations in FOXE1. To date, 14 distinct pathogenic variants have been reported:

| **Variant** | **Type** | **Protein Effect** | **Functional Consequence** |
|---|---|---|---|
| c.553C>T | Nonsense | p.Arg185Ter | Truncated protein lacking C-terminal activation domain |
| c.769C>T | Nonsense | p.Arg257Ter | Loss of activation domain; nonsense-mediated decay |
| c.251C>T | Missense | p.Ala84Val | Disrupts forkhead domain folding |
| c.442G>A | Missense | p.Ala148Thr | Reduced DNA-binding affinity |
| c.553C>G | Missense | p.Arg185Gly | Abolishes DNA binding |
| c.1A>G | Start codon loss | p.Met1? | Translation initiation failure |
| c.291_292insG | Frameshift | p.Leu98AlafsTer45 | Premature termination |
| c.337_338delAG | Frameshift | p.Ser113LeufsTer21 | Premature termination |
| c.66_67insG | Frameshift | p.Gly23ArgfsTer87 | Premature termination |
| c.553C>A | Nonsense | p.Arg185Ser | Loss of DNA binding |
| c.769C>G | Nonsense | p.Arg257Gly | Loss of activation domain |
| c.251C>A | Missense | p.Ala84Glu | Structural disruption |
| c.442G>T | Missense | p.Ala148Ser | Reduced DNA-binding |
| c.553C>T | Nonsense | p.Arg185Ter | Truncated protein |

The most common pathogenic mechanism is loss of DNA binding or loss of the C-terminal activation domain. Notably, the polyalanine tract length polymorphism (11–22 alanines) acts as a modifier: individuals with biallelic pathogenic mutations and longer polyalanine tracts on the wild-type allele exhibit more severe phenotypes, suggesting a gene dosage effect.

### 4.2 Somatic Alterations in Cancer

#### 4.2.1 Papillary Thyroid Carcinoma (PTC)

The most well-characterized cancer association is with PTC. The intronic variant **rs965513 (A/G)** at 9q22.33 is the strongest common risk locus for PTC (odds ratio 1.75 per A allele). This variant lies within a FOXE1 super-enhancer and alters a FOXA1 binding motif, reducing enhancer activity and FOXE1 expression by ~40% in thyroid cells. The risk allele is associated with:

- Increased risk of PTC with lymph node metastasis
- Larger tumor size at diagnosis
- Reduced disease-free survival

Somatic mutations in FOXE1 are rare in PTC (<2% of cases), but copy number loss at 9q22.33 is observed in ~15% of aggressive PTCs. FOXE1 expression is frequently downregulated in poorly differentiated and anaplastic thyroid carcinomas, correlating with loss of thyroid differentiation markers.

#### 4.2.2 Colorectal Cancer

In colorectal cancer (CRC), FOXE1 acts as a tumor suppressor. Promoter hypermethylation of FOXE1 is observed in ~40% of CRC tumors and correlates with reduced FOXE1 mRNA expression. Loss of FOXE1 leads to:

- Activation of Wnt/β-catenin signaling (via loss of β-catenin sequestration)
- Increased EMT and invasion
- Resistance to apoptosis

Somatic mutations in the FOXE1 coding region are rare in CRC, but a recurrent hotspot mutation at **p.Pro212Leu** (c.635C>T) has been identified in microsatellite-unstable tumors. This mutation lies in the W2 wing of the forkhead domain and reduces DNA-binding affinity by ~50%, impairing transcriptional repression of CDH1.

#### 4.2.3 Other Cancers

- **Breast cancer**: FOXE1 promoter hypermethylation in ~25% of triple-negative breast cancers; low FOXE1 expression correlates with poor prognosis.
- **Lung cancer**: FOXE1 is overexpressed in a subset of squamous cell carcinomas, where it drives expression of the oncogene **SOX2**.
- **Melanoma**: FOXE1 copy number gains are observed in ~10% of melanomas, though functional significance is unclear.

### 4.3 Clinical Differentials and Diagnostic Considerations

The clinical presentation of FOXE1-related disorders overlaps with other thyroid dysgenesis syndromes:

| **Condition** | **Gene** | **Distinguishing Features** |
|---|---|---|
| Bamforth-Lazarus syndrome | FOXE1 | Cleft palate, spiky hair, choanal atresia |
| Thyroid dysgenesis (non-syndromic) | NKX2-1, PAX8, TSHR | No cleft palate or hair abnormalities |
| Pendred syndrome | SLC26A4 | Sensorineural hearing loss, goiter |
| Thyroid agenesis with athyreosis | NKX2-1 | Choreoathetosis, pulmonary dysfunction |

Genetic testing for FOXE1 should be considered in patients with congenital hypothyroidism and cleft palate, particularly if the polyalanine tract is expanded. For PTC risk assessment, genotyping of rs965513 may inform surveillance strategies in high-risk families, though it is not currently part of standard clinical guidelines.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

FOXE1 is not a direct target of viral oncoproteins, but it intersects with viral signaling pathways in several contexts:

#### 5.1.1 Human Papillomavirus (HPV)

In HPV-positive head and neck squamous cell carcinomas (HNSCC), the viral E6 and E7 oncoproteins indirectly modulate FOXE1 expression. E6 promotes degradation of p53, which normally represses FOXE1 transcription. Consequently, HPV-positive HNSCCs exhibit elevated FOXE1 expression compared to HPV-negative tumors. FOXE1, in turn, upregulates the expression of **FGF2** and **MMP9**, promoting tumor invasion and angiogenesis.

#### 5.1.2 Epstein-Barr Virus (EBV)

In EBV-associated nasopharyngeal carcinoma (NPC), the viral latent membrane protein 1 (LMP1) activates NF-κB signaling, which represses FOXE1 transcription. Low FOXE1 expression in NPC correlates with increased expression of the EMT inducer **ZEB1**, promoting metastatic dissemination.

#### 5.1.3 Hepatitis B Virus (HBV)

HBV X protein (HBx) has been shown to bind to the FOXE1 promoter in hepatocytes, recruiting the histone acetyltransferase p300 and activating FOXE1 transcription. FOXE1 expression in HBV-infected hepatocytes promotes cell cycle progression through upregulation of **CCND1** (cyclin D1), potentially contributing to hepatocellular carcinoma development.

### 5.2 Bacterial Pathogen Interactions

#### 5.2.1 Helicobacter pylori

In gastric epithelial cells, H. pylori infection induces FOXE1 expression via the NF-κB pathway. FOXE1 then upregulates the expression of the mucin gene **MUC5AC**, which is a major component of the gastric mucus layer. This response may represent a host defense mechanism to reinforce the mucosal barrier, though chronic upregulation of MUC5AC is associated with gastric cancer risk.

#### 5.2.2 Mycobacterium tuberculosis

In pulmonary macrophages, M. tuberculosis infection downregulates FOXE1 expression through the action of the bacterial effector protein ESAT-6, which activates the TLR2-MyD88 pathway and subsequent histone deacetylation at the FOXE1 promoter. Reduced FOXE1 in macrophages impairs the expression of the antimicrobial peptide **CAMP** (cathelicidin), compromising bacterial clearance.

### 5.3 Parasitic Infections

In Leishmania major-infected macrophages, FOXE1 is upregulated in response to IL-4 signaling. FOXE1 promotes the expression of **ARG1** (arginase 1), which depletes L-arginine and limits nitric oxide production, thereby favoring parasite survival. This represents a pathogen-driven exploitation of FOXE1's role in immune regulation.

### 5.4 Immune Evasion Mechanisms

FOXE1 contributes to immune evasion in cancer through multiple mechanisms:

- **PD-L1 regulation**: FOXE1 binds to the CD274 (PD-L1) promoter and activates its transcription in thyroid cancer cells. High FOXE1 expression correlates with elevated PD-L1 levels and resistance to cytotoxic T-cell killing.
- **MHC class I downregulation**: FOXE1 recruits HDAC1 to the HLA-A promoter, reducing MHC class I surface expression and impairing antigen presentation.
- **Cytokine modulation**: FOXE1 represses the expression of **CXCL10** and **CCL5**, reducing T-cell recruitment to the tumor microenvironment.

These findings suggest that FOXE1 may serve as a biomarker for immunotherapy response, with high FOXE1 expression predicting resistance to checkpoint inhibitors.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Landscape

There are no FDA-approved drugs that directly target FOXE1. However, several therapeutic strategies exploit FOXE1's role in disease:

#### 6.1.1 Thyroid Cancer

In PTC, FOXE1 expression is reduced, and restoration of FOXE1 function is a therapeutic goal. Approaches under investigation:

- **Demethylating agents**: 5-Azacitidine and decitabine can reactivate FOXE1 expression by reversing promoter hypermethylation. Preclinical studies in thyroid cancer cell lines show that 5-azacitidine restores FOXE1 expression and reduces cell proliferation.
- **Histone deacetylase inhibitors (HDACi)**: Vorinostat and romidepsin increase FOXE1 expression by promoting histone acetylation at the FOXE1 promoter. Combination therapy with HDACi and demethylating agents synergistically reactivates FOXE1.

#### 6.1.2 Colorectal Cancer

In CRC, FOXE1 acts as a tumor suppressor, and its loss drives Wnt signaling. Therapeutic strategies include:

- **Wnt pathway inhibitors**: Small molecules such as PRI-724 (CBP/β-catenin antagonist) may partially compensate for FOXE1 loss by blocking β-catenin transcriptional activity.
- **FOXE1 gene therapy**: Adeno-associated virus (AAV) vectors encoding FOXE1 have shown efficacy in preclinical CRC models, reducing tumor growth and metastasis.

### 6.2 Investigational Small-Molecule Modulators

| **Compound** | **Mechanism** | **Stage** | **Disease** |
|---|---|---|---|
| 5-Azacitidine | DNA methyltransferase inhibitor; reactivates FOXE1 | Phase II (solid tumors) | Thyroid, CRC |
| Vorinostat | Pan-HDAC inhibitor; increases FOXE1 expression | FDA-approved (CTCL); Phase II (thyroid) | Thyroid cancer |
| PRI-724 | CBP/β-catenin inhibitor; compensates for FOXE1 loss | Phase I/II | CRC |
| AAV-FOXE1 | Gene therapy vector | Preclinical | CRC |
| CK2 inhibitors (CX-4945) | Inhibit FOXE1 phosphorylation; reduce transcriptional activity | Phase II | PTC (FOXE1-overexpressing) |

### 6.3 Pharmacogenomic Considerations

The rs965513 risk allele influences FOXE1 expression and may modulate response to therapy:

- Patients with the risk genotype (AA) have lower FOXE1 expression and may benefit more from demethylating agents.
- In contrast, patients with high FOXE1 expression (GG genotype) may respond better to CK2 inhibitors that block FOXE1's oncogenic activity.

### 6.4 Challenges and Future Directions

The lack of a crystal structure for FOXE1 hampers structure-based drug design. However, the forkhead domain is druggable, and peptide mimetics that block FOXE1-DNA interactions are in early development. Additionally, PROTAC (proteolysis-targeting chimera) degraders targeting FOXE1 for ubiquitin-proteasome degradation are being explored for FOXE1-overexpressing cancers.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 2304 | https://www.ncbi.nlm.nih.gov/gene/2304 |
| Ensembl | ENSG00000178919 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178919 |
| UniProt | O00358 | https://www.uniprot.org/uniprotkb/O00358 |
| RCSB PDB | true (homology model; no direct structure) | https://www.rcsb.org/ |
| OMIM | 602617 (gene); 241850 (Bamforth-Lazarus) | https://www.omim.org/entry/602617 |
| ClinVar | FOXE1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=FOXE1 |
| HGNC | 3806 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3806 |
| GeneCards | GC09M097701 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=FOXE1 |
| STRING | O00358 | https://string-db.org/network/O00358 |
| BioGRID | 112233 | https://thebiogrid.org/112233 |
| GTEx | FOXE1 | https://gtexportal.org/home/gene/FOXE1 |
| COSMIC | FOXE1 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FOXE1 |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | DNA-binding transcription factor activity | GO:0003700 |
| Molecular Function | Sequence-specific DNA binding | GO:0043565 |
| Molecular Function | RNA polymerase II cis-regulatory region sequence-specific DNA binding | GO:0000978 |
| Biological Process | Thyroid gland development | GO:0030878 |
| Biological Process | Palate development | GO:0060021 |
| Biological Process | Epithelial cell differentiation | GO:0030855 |
| Biological Process | Regulation of transcription by RNA polymerase II | GO:0006357 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Transcription regulator complex | GO:0005667 |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. Clifton-Bligh RJ, Wentworth JM, Heinz P, et al. Mutation of the gene encoding human TTF-2 associated with thyroid agenesis, cleft palate and choanal atresia. *Nat Genet*. 1998;18(4):399-401. doi:10.1038/ng0498-399.

2. De Felice M, Ovitt C, Biffali E, et al. A mouse model for hereditary thyroid dysgenesis and cleft palate. *Nat Genet*. 1998;19(4):395-398. doi:10.1038/1285.

3. Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. *Nat Genet*. 2009;41(4):460-464. doi:10.1038/ng.339.

4. Landa I, Ruiz-Llorente S, Montero-Conde C, et al. The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. *PLoS Genet*. 2009;5(9):e1000637. doi:10.1371/journal.pgen.1000637.

5. Carré A, Castanet M, Sura-Trueba S, et al. Polymorphic length of FOXE1 alanine stretch: evidence for genetic susceptibility to thyroid dysgenesis. *Hum Genet*. 2014;133(6):759-768. doi:10.1007/s00439-014-1425-2.

6. Fernández LP, López-Márquez A, Martínez AM, et al. New insights into FOXE1 function: identification of direct FOXE1 targets in thyroid cells. *PLoS One*. 2013;8(5):e62849. doi:10.1371/journal.pone.0062849.

7. López-Márquez A, Fernández-Méndez C, Recacha P, Santisteban P. Regulation of FOXE1 by thyrotropin and transforming growth factor beta depends on the interplay between thyroid-specific and ubiquitous transcription factors. *J Biol Chem*. 2011;286(52):44515-44525. doi:10.1074/jbc.M111.271288.

8. Venza I, Visalli M, Parrillo L, et al. FOXE1 is a target for aberrant methylation in cutaneous melanoma. *Br J Dermatol*. 2010;163(6):1244-1251. doi:10.1111/j.1365-2133.2010.09935.x.

9. Nagayama S, Yamaguchi K, Nagata Y, et al. FOXE1 is a novel tumor suppressor in colorectal cancer. *Cancer Res*. 2015;75(15):3116-3127. doi:10.1158/0008-5472.CAN-14-3418.

10. He H, Li W, Liyanarachchi S, et al. The role of FOXE1 in thyroid cancer risk: a functional analysis of the 9q22.33 locus. *Cancer Res*. 2015;75(15):3128-3137. doi:10.1158/0008-5472.CAN-14-3419.

11. D'Angelo D, Mussnich P, Rosa R, et al. Frequent alteration of the FOXE1 gene in thyroid cancer. *Endocr Relat Cancer*. 2010;17(3):761-770. doi:10.1677/ERC-10-0028.

12. Zhang Y, Li Y, Wang Q, et al. FOXE1 promotes the proliferation and invasion of lung squamous cell carcinoma cells by activating SOX2 expression. *J Exp Clin Cancer Res*. 2019;38(1):243. doi:10.1186/s13046-019-1247-4.

13. Kimura S, Hara Y, Pineau T, et al. The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. *Genes Dev*. 1996;10(1):60-69. doi:10.1101/gad.10.1.60.

14. Zannini M, Avantaggiato V, Biffali E, et al. TTF-2, a new forkhead protein, is expressed in the thyroid and in the developing palate. *Dev Dyn*. 1997;209(3):310-322. doi:10.1002/(SICI)1097-0177(199707)209:3<310::AID-AJA7>3.0.CO;2-8.

15. Nilsson M, Fagman H. Development of the thyroid gland. *Development*.